323 related articles for article (PubMed ID: 36503492)
1. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
Wang H; Lu X; Chen J
BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
3. Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing.
Huang L; Lou N; Xie T; Tang L; Han X; Shi Y
Cancer Immunol Immunother; 2023 Oct; 72(10):3259-3277. PubMed ID: 37458771
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
6. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
[TBL] [Abstract][Full Text] [Related]
7. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
8. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
[TBL] [Abstract][Full Text] [Related]
9. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
Front Immunol; 2022; 13():749241. PubMed ID: 35529878
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
11. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
Chang W; Li H; Cheng Y; He H; Ou W; Wang SY
Front Immunol; 2023; 14():1171145. PubMed ID: 37081889
[TBL] [Abstract][Full Text] [Related]
12. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
13. Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma.
Luo Y; Zhang S; Xie H; Su Q; He S; Lei Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):51-61. PubMed ID: 38279482
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
[TBL] [Abstract][Full Text] [Related]
15. An
Han Y; Wong FC; Wang D; Kahlert C
Cancer Inform; 2022; 21():11769351221100727. PubMed ID: 35645555
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J
Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
Front Immunol; 2022; 13():950001. PubMed ID: 36091041
[TBL] [Abstract][Full Text] [Related]
20. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
